Previous 10 | Next 10 |
Thinly traded argenx SE (NASDAQ: ARGX ) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (NYSE: JNJ ) $6.5B takeout of Momenta Pharmaceuticals (NASDAQ: MNTA ) . More news on: argenx SE, Johnson & Johnson, Momenta Pharmaceuticals, Inc., He...
Johnson & Johnson (NYSE: JNJ ) has agreed to acquire Momenta Pharmaceuticals (NASDAQ: MNTA ) for $52.50 per share in cash for a total of $6.5B. More news on: Johnson & Johnson, Momenta Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition...
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020 Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatme...
Without any meaningful revenue, Momenta Pharmaceuticals ' (NASDAQ: MNTA) second-quarter report was rather uneventful, so it's a little surprising to see shares down 13.5% today without any significant news.But perhaps the lack of news is what's making short-term investors head for the exits. ...
Momenta Pharmaceuticals, Inc. (MNTA) Q2 2020 Results Conference Call August 10, 2020 08:30 AM ET Company Participants Patty Eisenhaur - VP, IR and Corporate Communication Craig Wheeler - President and CEO Young Kwon - Chief Financial and Business Officer Santiago Arroyo - Chief...
Gainers: Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...
The following slide deck was published by Momenta Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Momenta Pharmaceuticals (NASDAQ: MNTA ) : Q2 GAAP EPS of -$0.48 misses by $0.07 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between IgG reduction and MG-ADL clinical benefit in MG; full data expected by Q4 2020 – ...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results...
News, Short Squeeze, Breakout and More Instantly...
Momenta Pharmaceuticals Inc. Company Name:
MNTA Stock Symbol:
NASDAQ Market:
Momenta Pharmaceuticals Inc. Website:
Are These Top 3 Pharmaceutical Stocks On Your October Watchlist? Investing in pharmaceutical stocks is a popular trend in times of political or economic instability. This is because the demand for drugs will still be steady all year long, no matter what is happening in the world...
Chesapeake Utilities to Join S&P SmallCap 600 Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals In...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...